These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 10634204)
21. In vitro combination of amdoxovir and the inosine monophosphate dehydrogenase inhibitors mycophenolic acid and ribavirin demonstrates potent activity against wild-type and drug-resistant variants of human immunodeficiency virus type 1. Borroto-Esoda K; Myrick F; Feng J; Jeffrey J; Furman P Antimicrob Agents Chemother; 2004 Nov; 48(11):4387-94. PubMed ID: 15504868 [TBL] [Abstract][Full Text] [Related]
26. Current insights into reverse transcriptase inhibitor-associated resistance. Wainberg MA; White AJ Antivir Ther; 2001; 6 Suppl 2():11-9. PubMed ID: 11678474 [No Abstract] [Full Text] [Related]
27. Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study. Llibre JM; Bonjoch A; Iribarren J; Galindo MJ; Negredo E; Domingo P; Pérez-Alvarez N; Martinez-Picado J; Schapiro J; Clotet B; HIV Med; 2008 Aug; 9(7):508-13. PubMed ID: 18484978 [TBL] [Abstract][Full Text] [Related]
28. Early intensification with abacavir in subjects at high risk for incomplete viral suppression. Bartlett JA; Tebas P; Bassett R; Huang W; Kuritzkes D; Reisler R; Loyack N; Robison K; Antivir Ther; 2003 Aug; 8(4):361-3. PubMed ID: 14518706 [No Abstract] [Full Text] [Related]
29. Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir. Ochoa de Echagüen A; Arnedo M; Xercavins M; Martinez E; Rosón B; Ribera E; Domingo P; González A; Riera M; Llibre JM; Gatell JM; Dalmau D; AIDS; 2005 Sep; 19(13):1385-91. PubMed ID: 16103769 [TBL] [Abstract][Full Text] [Related]
30. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV. Stürmer M; Staszewski S; Doerr HW Antivir Ther; 2007; 12(5):695-703. PubMed ID: 17713153 [TBL] [Abstract][Full Text] [Related]
31. Identification of reverse transcriptase mutations associated with HIV-1 drug resistance mainly against non-nucleoside reverse transcriptase inhibitors in treatment-naive patients. Magiorkinis E; Paraskevis D; Lazanas M; Kiosses VG; Gargalianos P; Hatzakis A AIDS; 1999 Jul; 13(10):1276-8. PubMed ID: 10416535 [No Abstract] [Full Text] [Related]
32. [Current situation of nucleoside reverse transcriptase inhibitors]. Ngo Van P Ann Med Interne (Paris); 2000 Jun; 151(4):255-9. PubMed ID: 10922952 [TBL] [Abstract][Full Text] [Related]
33. In vitro anti-HIV-1 synergy between non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz. Kollmann C; Tremblay C; Giguel F; Chou TC; Hirsch MS Antivir Ther; 2001 Jun; 6(2):143-4. PubMed ID: 11491419 [No Abstract] [Full Text] [Related]
34. Mycophenylate - a potential new option. Proj Inf Perspect; 1999 Sep; (28):9. PubMed ID: 11367367 [TBL] [Abstract][Full Text] [Related]